Klaria Pharma Holding AB (publ)

Climate Impact & Sustainability Data (2017)

Klaria became a member of the Medical Technology Enterprise Consortium (MTEC), a US consortium.

High risk level in the pharmaceutical development business, no guarantee of successful product development, obtaining necessary permits, or market acceptance of launched drugs.
Potential side effects of products could delay or halt product development and limit or prevent commercial use.
Intense competition in the industry.
Regulatory risks and uncertainties regarding approvals and market access.
Dependence on collaborations with distributors and other distribution channels.
Risk of patent infringement.
Product liability risks.
Dependence on key personnel.
Risk of insufficient patent protection.
Currency risk due to future sales primarily in foreign currencies.
Growth and recruitment needs.
Liquidity risk in the stock.
Legal risks related to operating in multiple countries.

Maintaining product liability insurance.
Securing a licensing agreement with Purdue Pharma (Canada) for KL-00514 (naloxone) for opioid overdose treatment, including financial support and access to the global market.
Establishing collaborations in drug development and regulatory expertise.
Analyzing the effects of IFRS 15 and IFRS 9 on the company's financial statements.

Climate Change Data